MCM
SPRO icon

Monimus Capital Management’s Spero Therapeutics SPRO Stock Holding History

Monimus Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-310,908
Closed -$902K – 69
2025
Q2 		$902K Hold
310,908
– – 0.66% 42
2025
Q1 		$224K Hold
310,908
– – 0.19% 47
2024
Q4 		$320K Buy
+310,908
New +$370K 0.3% 48

Other funds holding SPRO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return
ICM
Ionic Capital Management New York $690M AUM 70.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Monimus Capital Management's SPRO Position: Q3 2025 in Review

Monimus Capital Management sold out of Spero Therapeutics (SPRO) in Q3 2025, closing a stake of 310,908 shares — an estimated $902K sold.

Monimus Capital Management first reported a position in SPRO in Q4 2024 and held it in 3 quarters. The position peaked at $902K in Q2 2025. 47 funds tracked by Wall St. Rank hold SPRO as of Q3 2025.

  • Monimus Capital Management reported no remaining Spero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Monimus Capital Management sold 310,908 Spero Therapeutics shares in Q3 2025, an estimated $902K.
  • Monimus Capital Management first reported a position in Spero Therapeutics in Q4 2024 and held it in 3 quarters.
  • Monimus Capital Management's Spero Therapeutics position peaked at $902K in Q2 2025.
  • 47 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2025.

Based on Monimus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.